Pentixapharm's Pivotal Phase 3 Study on PANDA Progresses, Webcast Scheduled for November 12, 2026#Germany#Berlin#radiopharmaceuticals#Pentixapharm#PANDA_Study
Pentixapharm's Pivotal Phase 3 Study on PANDA Progresses, Webcast Scheduled for November 12, 2026
Pentixapharm Holding AG reports significant progress in its Phase 3 PANDA study, aimed at tackling primary aldosteronism, with a webcast set for November 12, 2026.
third-news.com
November 4, 2026 at 7:34 AM
Pentixapharm's Pivotal Phase 3 Study on PANDA Progresses, Webcast Scheduled for November 12, 2026#Germany#Berlin#radiopharmaceuticals#Pentixapharm#PANDA_Study
Pentixapharm Receives FDA Approval for Innovative Cardiovascular Diagnostic Study#Germany#Berlin#Pentixapharm#CXCR4#PANDA_Study
Pentixapharm Receives FDA Approval for Innovative Cardiovascular Diagnostic Study
Pentixapharm has achieved FDA clearance to start its Phase 3 PANDA study, focusing on a groundbreaking diagnostic approach for cardiovascular health.
third-news.com
June 9, 2026 at 7:19 AM
Pentixapharm Receives FDA Approval for Innovative Cardiovascular Diagnostic Study#Germany#Berlin#Pentixapharm#CXCR4#PANDA_Study